(Trimethoxyphenylamino) Pyrimidinyl Formulations
AssigneeRigel Pharmaceuticals, Inc.
InventorsBindhumadhavan Gururajan, Farhan Abdul Karim Alhusban, Ian Paul Gabbott, Dawn Sievwright, David Bradley Brook Simpson
Life of this patent
Estimating the term…
Abstract
There are provided pharmaceutical compositions comprising greater than 15% w/w of a compound of Formula (I) as defined herein and/or hydrate thereof and an amount of one or more effervescent agents that is sufficient to provide satisfactory in vitro dissolution; and further comprising one or more pharmaceutically acceptable ingredients; and to processes for obtaining them.
Claims25
1-9. (canceled)
A method of treating a patient for rheumatoid arthritis, which method comprises administering to said patient a pharmaceutical composition comprising greater than 15% w/w of the compound of Formula (I):
- wherein each X+ represents a monovalent cation;
- and/or a hydrate thereof;
- and an amount of one or more effervescent agents that is sufficient to provide satisfactory in vitro dissolution at low pH;
- and
- further comprising one or more pharmaceutically acceptable ingredients.
A method of treating a patient for cancer, which method comprises administering to said patient a pharmaceutical composition comprising greater than 15% w/w of the compound of Formula (I):
- wherein each X+ represents a monovalent cation;
- and/or a hydrate thereof;
- and an amount of one or more effervescent agents that is sufficient to provide satisfactory in vitro dissolution at low pH;
- and
- further comprising one or more pharmaceutically acceptable ingredients.
A method of treating a patient for systemic lupus erythematosus, which method comprises administering to said patient a pharmaceutical composition comprising greater than 15% w/w of the compound of Formula (I):
- wherein each X+ represents a monovalent cation;
- and/or a hydrate thereof;
- and an amount of one or more effervescent agents that is sufficient to provide satisfactory in vitro dissolution at low pH;
- and
- further comprising one or more pharmaceutically acceptable ingredients.
A method of treating a patient for rheumatoid arthritis, which method comprises administering to said patient unit dosage form comprising greater than or equal to 60 mg of the compound of Formula (I):
- wherein each X+ represents a monovalent cation;
- and/or hydrate thereof and less than or equal to 110 mg of one or more effervescent agents sufficient to provide satisfactory in vitro dissolution at low pH;
- and further comprising one or more pharmaceutically acceptable ingredients.
A method of treating a patient for cancer, which method comprises administering to said patient unit dosage form comprising greater than or equal to 60 mg of the compound of Formula (I):
- wherein each X+ represents a monovalent cation;
- and/or hydrate thereof and less than or equal to 110 mg of one or more effervescent agents sufficient to provide satisfactory in vitro dissolution at low pH;
- and further comprising one or more pharmaceutically acceptable ingredients.
A method of treating a patient for systemic lupus erythematosus, which method comprises administering to said patient unit dosage form comprising greater than or equal to 60 mg of the compound of Formula (I):
- wherein each X+ represents a monovalent cation;
- and/or hydrate thereof and less than or equal to 110 mg of one or more effervescent agents sufficient to provide satisfactory in vitro dissolution at low pH;
- and further comprising one or more pharmaceutically acceptable ingredients.
A method of treating a patient for immune thrombocytic purpura, which method comprises administering to said patient a pharmaceutical composition comprising greater than 15% w/w of the compound of Formula (I):
- wherein each X+ represents a monovalent cation;
- and/or a hydrate thereof;
- and an amount of one or more effervescent agents that is sufficient to provide satisfactory in vitro dissolution at low pH;
- and
- further comprising one or more pharmaceutically acceptable ingredients.
A method of treating a patient for immune thrombocytic purpura, which method comprises administering to said patient unit dosage form comprising greater than or equal to 60 mg of the compound of Formula (I):
- wherein each X+ represents a monovalent cation;
- and/or hydrate thereof and less than or equal to 110 mg of one or more effervescent agents sufficient to provide satisfactory in vitro dissolution at low pH;
- and further comprising one or more pharmaceutically acceptable ingredients.
Dependencies are inferred from the claim text.